RE:RE:T-VecShould read .."fully discussed" on this message board.
As had been repeatedly stated in the past the positive effects of ONCY's pelareorep in combination with other I/O agents such as immune checkpoint inhibitors I'd that pelareorep "primes" the immune system in advance of the administration of a PD-(L)1 inhibitor, for example, by remodeling the tumor microenvironment (TME) with otherwise is hostile to checkpoint inhibitors. In addition pelareorep increases PD-(L)1 expression on the tumor cell thus enhancing the number of PD-1 binding sites on the tumor and by doing so can turn "cold" tumors into "hot" tumors.
The benefit of the Phase 1bT-Vec study is that the study researchers unequivocally confirmed the above findings with pelareorep and that without sequencing the addition of the checkpoint inhibitor several days after the administration of the OV, the immune system cannot become primed and the TME cannot be remodeled.